Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II individualized chemotherapy selection in advanced pancreatic cancer based on tumor therapeutic targets
2011-001017-13Phase 2Terminated
- Sponsor
- Spanish National Cancer Research Centre
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, fluorouracil, capecitabine, oxaliplatin, irinotecan and 1 more in pancreatic cancer (PC), sponsored by Spanish National Cancer Research Centre. Primary endpoints: overall survival and 12-month survival rate. Started Sep 2011; status: terminated.
02
Drugs
gemcitabinefluorouracilcapecitabineoxaliplatinirinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2011-001017-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001017-13.